Table 1 Participant characteristics
N | 630 | |
|---|---|---|
Demographics | ||
Sex | % females | 61.6% |
Age (in years) | Mean (SD) | 51.2 (5.5) |
Education (in years) | Mean (SD) | 16.7 (3.4) |
APOE4 | % carriers | 38.4% |
APOE2 | % carriers | 8.4% |
Hypertension | % positive | 16.5% |
Hyperlipidaemia | % positive | 12.1% |
Diabetes mellitus | % positive | 2.7% |
Obese | % positive | 26.2% |
Excessive alcohol consumption | % positive | 14.1% |
Hearing impairment | % positive | 10.8% |
Traumatic brain injury | % positive | 35.4% |
Medication | ||
Anti-hypertensive medication | % on medication | 7.3% |
Anti-hyperlipidemic medication | % on medication | 5.2% |
Anti-diabetic medication | % on medication | 6.2% |
SVD markers | ||
WMH volume (% of TIV) | Mean (SD) | 0.13 (0.16) |
Lacunes (present/absent) | % present | 10.5% |
Cerebral microbleeds (present/absent) | % present | 16.8% |
Enlarged perivascular spaces (range 0–4) | Mean (SD) | 0.94 (0.49) |
Composite SVD scores | ||
Global SVD (range 0–4) | Mean (SD) | 0.44 (0.72) |
CAA (range 0–4) | Mean (SD) | 0.49 (0.69) |
Hypertensive arteriopathy (range 0–4) | Mean (SD) | 0.27 (0.60) |